i-Lumen Scientific Achieves FDA Approval to Begin U.S. Enrollment in Pivotal i-SIGHT2 Clinical Study Targeting Dry AMD i-Lumen Scientific has received FDA Investigational Device Exemption to initiate U.S. enrollment in the i-SIGHT2 clinical study for treating dry AMD, a major vision loss cause.

i-Lumen Scientific Achieves FDA Approval to Begin U.S. Enrollment in Pivotal i-SIGHT2 Clinical Study Targeting Dry AMD #USA #Bloomington #Dry_AMD #i-SIGHT2 #i-Lumen_Scientific

i-Lumen Scientific Advances in Treatment for Dry AMD with FDA Approval to Commence U.S. Enrollment i-Lumen Scientific's non-invasive method for treating dry AMD receives FDA clearance to begin patient recruitment in the U.S. for an ongoing clinical study.

i-Lumen Scientific Advances in Treatment for Dry AMD with FDA Approval to Commence U.S. Enrollment #United_States #Bloomington #Dry_AMD #i-Lumen #i-SIGHT2

Avirmax Biopharma Inc. Showcases Groundbreaking Research at the ARVO 2025 Annual Meeting Avirmax Biopharma is set to make a significant impact at the 2025 ARVO meeting with multiple presentations focused on ocular gene therapy advancements through its proprietary technologies.

Avirmax Biopharma Inc. Showcases Groundbreaking Research at the ARVO 2025 Annual Meeting #Avirmax_Biopharma #AAV_Gene_Therapy #Dry_AMD